Surgical Science Sweden AB (SE:SUS)
:SUS
Want to see SE:SUS full AI Analyst Report?
SUS Stock Chart & Stats
kr84.50
-kr3.20(-2.25%)
At close: 4:00 PM EST
kr84.50
-kr3.20(-2.25%)
Day’s Range― - ―
52-Week Rangekr23.70 - kr162.60
Previous CloseN/A
Volume39.18K
Average Volume (3M)1.61M
Market Cap
kr1.92B
Enterprise Valuekr1.24B
Total Cash (Recent Filing)kr667.73M
Total Debt (Recent Filing)kr2.15M
Price to Earnings (P/E)20.8
Beta0.52
Next Earnings
Aug 19, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.03
Shares Outstanding51,026,237
10 Day Avg. Volume583,608
30 Day Avg. Volume1,614,194
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.97
Revenue Forecast (FY)kr995.58M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetAn exceptionally conservative balance sheet with near-zero leverage and substantial net cash provides durable financial flexibility. It supports sustained R&D, production scaling and M&A optionality, cushions FX and timing shocks, and reduces insolvency risk over the next 2–6 months.
Positive Cash GenerationRebounding operating cash flow and positive free cash flow indicate the business can self-fund growth and investments. Reliable cash generation supports product development, production capacity upgrades and margin initiatives without immediate external financing, improving long-term resilience.
Robotics Pipeline DiversificationExpanding robotics partnerships beyond a single OEM reduces customer-concentration risk and creates a larger, structural addressable market for recurring license income. A broader robotics pipeline supports sustainable licensing growth as surgical robotics adoption increases over time.
Bears Say
Compressed ProfitabilityMaterial margin compression versus prior years signals weaker operating leverage or higher recurring costs. Sustained lower EBIT and net margins constrain reinvestment capacity and returns on capital, making margin recovery crucial for maintaining long-term profitability and shareholder returns.
Intuitive License Revenue ReversionA known contractual reversion with a major robotics partner will materially reduce 2026 license revenue. This structural revenue loss exposes the company to near-term top-line pressure and highlights dependence on large OEM agreements until alternative robotics customers scale their purchases.
Structural China HeadwindsPolicy-driven preference for domestic suppliers in China creates a persistent competitive disadvantage for simulator sales there. This reduces long-term addressable market in a major region, forces strategic local investment to remain relevant, and may depress growth versus peers.
Surgical Science Sweden AB News
SUS FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr162.60 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is kr1.92B.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Aug 19, 2026 which is in 89 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on May 20, 2026. The company reported kr0.37 earnings per share for the quarter, beating the consensus estimate of kr0.305 by kr0.065.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.4.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of kr0.37 in its last earnings report, beating expectations of kr0.305. Following the earnings report the stock price went up 12.785%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SE:SUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Senzime AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Saniona AB
―
C-Rad AB Class B
―
Options Prices
Currently, No data available
---